



Editorial

Mycophenolate Mofetil Use for Inflammatory Bowel Disease

Ahmed Abomhya^{1,*}, Ahmed Elmoursi²

1-Department of Gastroenterology University of Kentucky Lexington, KY, USA

2-Division of Rheumatology, Allergy, and Immunology, Department of Medicine Massachusetts General Hospital; Harvard Medical School Boston, MA, USA

ARTICLE INFO

Article history:

Received 18 Mar. 2025

Received in revised form 06 Apr. 2025

Accepted 06 Apr. 2025

Published 14 Apr. 2025

Keywords:

Mycophenolate Mofetil

Inflammatory Bowel Disease

Ulcerative Colitis

Crohn's Disease

Immunosuppressive Therapy

Anti-inflammatory Agents

Immunomodulators

Gastrointestinal Inflammation

Mycophenolic Acid

EDITORIAL

Mycophenolate Mofetil (MMF) is a prodrug that gets converted to mycophenolic acid (MPA). MPA inhibits the Akt/mTOR and STAT5 pathways and has a reversible cytostatic effect on T and B lymphocytes [1].

MMF is FDA-approved for immunosuppressive therapy after solid organ transplantation. MMF has been used for multiple inflammatory/autoimmune conditions including psoriasis, dermatomyositis, autoimmune hepatitis, lupus erythematosus, myasthenia gravis, and Takayasu arteritis [2].

In this Editorial, we discuss the recently published systematic review and meta-analysis by Balassiano et al [3]. This systematic review and meta-analysis studied the use of MMF for the treatment of IBD patients. This review included both retrospective studies, case series, and clinical trials that evaluated the use of MMF in patients with IBD. Included patients were intolerant or unresponsive to Azathioprine. MMF was used in the included studies for induction and maintenance of remission, or as a steroid-sparing agent/immunomodulator. This study demonstrated MMF's efficacy in both induction and maintenance of remission in IBD patients. MMF was associated with added benefits for patients on steroids as well as those on anti-TNF therapy [3].

MMF has several boxed warnings in the United States, limiting its use outside FDA-approved indications. MMF should be prescribed only by healthcare providers experienced in immunosuppressive therapy and organ transplant management, with access to comprehensive laboratory and medical resources [4].

There is also a significant risk of infections associated with immunosuppression, including but not limited to opportunistic infections, which may result in significant morbidity and mortality. MMF use is associated with an increased risk of malignancy, including but not limited to lymphoma and skin cancers. There is also a boxed warning suggesting avoiding MMF use in pregnancy if alternative therapies are available, as its use is associated with congenital malformation and first-trimester pregnancy loss [5].

MMF has been associated with endoscopic findings that could be similar to acute colitis, IBD, ischemia, and graft-versus-host disease. Development of such side effects or endoscopic findings can lead to discontinuation of treatment, treatment interruption, or medication non-compliance [6, 7].

In this study, the pooled event rate for adverse events was 26.1% (20.3%-32.8%). The side effect profile is crucial in determining the role of MMF in IBD treatment. The IBD field is evolving around a patient-centered approach when it comes to therapeutic selection. IBDologists extensively discuss potential side effects and explore the patient's risk appetite. In general, more than one in four is considered a relatively high risk.

While side effects could constitute a major challenge for MMF use in IBD patients, their impact on treatment adherence, disease progression, and quality of life must be carefully weighed against MMF's potential benefits. The development of side effects has been associated with specific risk factors that increase the risk of developing side effects, which could open the door for drug adjustment and close monitoring that might allow its use. These risk factors include using a non-enteric-coated formulation, increased MMF blood levels, concomitant use of other immunosuppressant agents like calcineurin inhibitors, and female sex [8, 9, 10, 11].

* Corresponding author: Ahmed Abomhya, Department of Gastroenterology, University of Kentucky, Lexington, KY 40508, USA. Email: ahmedabdsatar78@gmail.com

Published by the American Society for Inclusion, Diversity, and Equity in Healthcare (ASIDE). ISSN (Print): 3066-4004, ISSN (Online): 3066-4012. © 2025 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0). Hosting by ASIDE Journals.

Citation: Abomhya A, Elmoursi A. Mycophenolate Mofetil Use for Inflammatory Bowel Disease. ASIDE GI. 2025;1(2):1-2, doi:10.71079/ASIDE.GI.04142552

MMF is relatively inexpensive compared to other IBD therapies. A dose price can range from as low as \$0.32 for an oral dose to as high as \$129.57 for an IV dose. This is cheaper compared to Azathioprine prices [12]. With the evolving widespread use of biosimilars, we are heading to an era with better accessibility to advanced IBD therapies, and this will allow gastroenterologists to adopt the recommended top-down approach in therapeutic selection [13].

The ACG guidelines for Crohn's disease recommend combining an immunomodulator with anti-TNF rather than using anti-TNF alone [14]. Hernandez-Camba et al. showed the added benefits of anti-TNF when combined with MMF [15]. This suggests potential benefits of MMF as an immunomodulator that could decrease anti-TNF immunogenicity and decrease the risk of secondary non-response.

The study has some significant limitations. The included studies had heterogeneous designs. The study lacked a control group and did not compare MMF to alternatives such as Azathioprine or Mercaptopurine.

The IBD therapies are expanding, and it's an evolving field with multiple advancements annually. Selection of therapy in patients with IBD is a multi-step and complex process that involves close consideration of the disease stage, patient population, disease complications, medication history, prognostic factors, presence of extra-intestinal manifestations of IBD, potential side effects of medications, patients' preferences, and cost implications [14].

In conclusion, this study highlights the potential benefits of MMF as a steroid-sparing agent or as an immunomodulator in conjunction with anti-TNF. It provides evidence for the use of MMF as an alternative for those intolerant or unresponsive to Azathioprine and Methotrexate.

Conflicts of Interest

The authors declare no competing interests that could have influenced the objectivity or outcome of this research

Funding Source

The authors declare that no specific grant or funding was received for this research from any public, commercial, or not-for-profit funding agency.

Acknowledgments

None

Institutional Review Board (IRB)

None

Large-Language Model

None

Authors' Contribution

All authors have contributed equally to the conception, drafting, review, and final approval of this manuscript. Each author has read and agreed to the final version for publication.

Data Availability

The data that support the findings of this study are openly available, as cited in the article.

References

- Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. *Immunopharmacology*. 2000;47(2-3):85-118. [PMID: 10878285, [https://doi.org/10.1016/s0162-3109\(00\)00188-0](https://doi.org/10.1016/s0162-3109(00)00188-0)].
- Alakkas Z, Gari AM, Makhdoum S, AlSindi EA. Mycophenolate-induced colitis in a patient with lupus nephritis: a case report and review of the literature. *J Med Case Rep*. 2024;18(1):229. [PMID: 38689344, PMCID: PMC11061913, <https://doi.org/10.1186/s13256-024-04539-7>].
- Balassiano N, Tidwell J, Abdelhalim O, Abusuliman M, Nassar M, Beran A, et al. Mycophenolate Mofetil for the Treatment of Resistant Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. *ASIDE Gastroenterology*. 2025;1(1):15-22. [<https://doi.org/10.71079/ASIDE.GI.03132515>].
- Kim M, Rostas S, Gabardi S. Mycophenolate fetal toxicity and risk evaluation and mitigation strategies. *Am J Transplant*. 2013;13(6):1383-9. [PMID: 23617812, <https://doi.org/10.1111/ajt.12238>].
- Pisoni CN, D'Cruz DP. The safety of mycophenolate mofetil in pregnancy. *Expert Opin Drug Saf*. 2008;7(3):219-22. [PMID: 18462179, <https://doi.org/10.1517/14740338.7.3.219>].
- Calmet FH, Yarur AJ, Pukazhendhi G, Ahmad J, Bhamidimarri KR. Endoscopic and histological features of mycophenolate mofetil colitis in patients after solid organ transplantation. *Ann Gastroenterol*. 2015;28(3):366-73. [PMID: 26126799, PMCID: PMC4480174].
- de Andrade LG, Rodrigues MA, Romeiro FG, Garcia PD, Contti MM, de Carvalho MF. Clinicopathologic features and outcome of mycophenolate-induced colitis in renal transplant recipients. *Clin Transplant*. 2014;28(11):1244-8. [PMID: 25142167, <https://doi.org/10.1111/ctr.12452>].
- Arns W. Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity? *Transplant Proc*. 2007;39(1):88-93. [PMID: 17275481, <https://doi.org/10.1016/j.transproceed.2006.10.189>].
- Kiang TKL, Ensom MHH. Exposure-Toxicity Relationships of Mycophenolic Acid in Adult Kidney Transplant Patients. *Clin Pharmacokinet*. 2019;58(12):1533-52. [PMID: 31332670, <https://doi.org/10.1007/s40262-019-00802-z>].
- Langone AJ, Chan L, Bolin P, Cooper M. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study. *Transplantation*. 2011;91(4):470-8. [PMID: 21245794, <https://doi.org/10.1097/TP.0b013e318205568c>].
- Meaney CJ, Sudchada P, Consiglio JD, Wilding GE, Cooper LM, Venuto RC, et al. Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant. *J Clin Pharmacol*. 2019;59(10):1351-65. [PMID: 31062373, PMCID: PMC7375007, <https://doi.org/10.1002/jcph.1428>].
- Tse KC, Tang CSO, Lam MF, Yap DYH, Chan TM. Cost Comparison Between Mycophenolate Mofetil and Cyclophosphamide-Azathioprine in the Treatment of Lupus Nephritis. *The Journal of Rheumatology*. 2009;36(1):76-81. [<https://doi.org/10.3899/jrheum.080517>].
- Satsangi J, Nowak J, Kalla R, Colombel JF. Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial. *Lancet Gastroenterol Hepatol*. 2024;9(7):591-2. [PMID: 38870964, [https://doi.org/10.1016/S2468-1253\(24\)00082-7](https://doi.org/10.1016/S2468-1253(24)00082-7)].
- Lichtenstein GR, Loftus EV Jr, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. Correction: ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol*. 2018;113(7):1101. [PMID: 29895986, <https://doi.org/10.1038/s41395-018-0120-x>].
- Hernandez-Camba A, Arranz L, Vera I, Carpio D, Calafat M, Lucendo AJ, et al. Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry. *Dig Liver Dis*. 2022;54(5):635-41. [PMID: 34862115, <https://doi.org/10.1016/j.dld.2021.10.002>].